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Introduction
Articular cartilage is highly capable of withstanding repeated loading, considerable stress, 
and friction. However, unlike other types of connective tissue, it has very low capacity to repair 
due to the lack of nerves, blood vessels and lymphatics [1]. It was shown in previous studies [2] 
that treating primary chondrocyte monolayers with 1 µM of WIN55, 212-2 increased the rate of 
wound closure and cell proliferation and those treating primary chondrocyte monolayers with 
2 µM of the same synthetic cannabinoid decreased rate of wound closure and cell proliferation. 
Moreover, both treatments notably reduced cell lengths, but by different percentages. These results 
prompted further investigation of the effect of WIN55, 212-2 (WIN-2) on chondrocyte protein 
expression. Understanding the mechanisms regulating cellular behaviour, e.g. proliferation, 
migration, morphology, phenotype and cell adhesion is crucial for tissue engineering [3]. Cells 
receptor membranes bind to their ligands by expressing different types of integrins depending on 
the extracellular matrix [4]. Furthermore, functionality of cells relies in part on the extra cellular 
matrix (ECM) protein surrounding the cell [5]. For instance, collagen type-II rich ECM promotes 
chondrocyte proliferation and differentiation [6].
Normally, chondrocytes within articular cartilage demonstrate a star-shaped morphology 
while secreting various ECM proteins including type-II collagen, cartilage oligomeric matrix 
protein (COMP) and aggrecan [7,8]. Nevertheless, chondrocyte dedifferentiation has been noted 
in osteoarthritic cartilage [8,9]. There is evidence that culturing chondrocytes in monolayers 
encourages the cells to lose their rounded shape and dedifferentiate into fibroblast-like morphology 
and produce collagen type-1 [10]. Therefore, collagen type-II can be used as a chondrocytic marker 
and both collagens can be used to determine the differentiation state of chondrocytes. Also, one 
of the major problems facing current cartilage repair strategies is the formation of fibrocartilage 
instead of articular cartilage due to the dedifferentiation of chondrocytes into fibrocytes. Thus, the 
present study was designed to investigate effect of WIN-2 on chondrocyte differentiation using 
immunofluorescence microscopy and validated quantitatively with an Elisa based method. Further 
experiments were also carried out to investigate the effect of WIN-2 on S100 protein which is 
considered useful for the histological evaluation of human articular cartilage repair activity [11]. It 
is known that S100 is an in vitro antigen synthesised by primary chondrocytes [12].
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Abstract
Studies have been conducted to highlight the anti-inflammatory and immunosuppressive properties of 
synthetic cannabinoids as well as their potential for cartilage repair. Various wound healing techniques can be 
used to investigate the mechanisms of chondrocyte repair in monolayers or three dimensional tissues constructs. 
In this work the effect of WIN55, 212-2 (WIN-2) on nitric oxide (NO) and matrix metalloproteinase-2 (MMP-2) 
expressed by wounded chondrocyte monolayers was investigated. Moreover, expression of collagen type-I and 
type-II, fibronectin and S100 proteins were detected using immunofluorescence and quantitatively verified using 
ELISA based techniques following treatment with 1 µM and 2 µM of WIN-2. Treating chondrocytes with 1 µM 
of WIN-2 significantly increased expression of collagen type-II, fibronectin and S100, and significantly reduced 
collagen type-I expressions as compared to the control groups. On the other hand, both concentrations of WIN-2 
significantly reduced the expression of the inflammation markers NO and MMP-2 in a dose dependent manner. 
These findings highlight the potential use of the synthetic cannabinoids for improving cartilage healing properties 
as well as acting as an anti-inflammatory agent which could be used to enhance tissue engineering protocols 
aimed at cartilage repair.
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It is well established that fibronectin is a high-molecular weight 
glycoprotein of the ECM that binds to other ECM components via 
integrins such as heparan sulfate proteoglycans, fibrin and collagen 
[13] and that chondrocytes secrete fibronectin in the soluble form, 
which is then assembled into an insoluble matrix in a complex cell-
mediated process [14]. It plays a key role in cell migration, adhesion, 
differentiation and growth, which increase its importance in processes 
such as wound healing and embryonic development [13]. In wound 
healing of connective tissue, fibronectin is vital for the remodelling 
and resynthesis of the tissue matrix [15]. On the other hand, changes 
in fibronectin organization, degradation and expression have been 
identified in a number of pathologies, including cancer and fibrosis 
[16]. Proteases including MMPs that digest the plasma fibronectin 
are secreted at wound sites and hence cells secrete cellular fibronectin 
and assemble it into an insoluble matrix [17].
The dissolution and maintenance of the extracellular matrix is 
mediated in part by the Matrix Metalloproteinase (MMP) family 
of enzymes and by their inhibitors, i.e. the Tissue Inhibitors of 
Metalloproteinases (TIMPs) [18]. Further, cartilage ECM may 
introduce a physical barrier, since some cells might be able to 
squeeze through matrix meshwork [19], while others may need to 
use proteolytic enzymes to migrate through condensed cartilage 
matrices [20]. It will be important to address the effect that WIN-2 
has on fibronectin and proteolytic enzymes such as MMP-2 (matrix 
metalloproteinase-2), as the rise in chondrocytic proteases caused by 
osteoarthritis [21] may aid cell motility.
NO is thought to interfere with chondrocyte migration and 
attachment to fibronectin and cause cell death [22]. However, other 
studies have suggested that NO by itself is not cytotoxic to cultured 
chondrocytes and can even have a protective role, while it only causes 
cell death under conditions where other Reactive Oxygen Species 
(ROS) are also generated [23]. These resulted in further investigation 
of its role in monolayer chondrocyte wound healing described in this 
work. Griess reagent has been used to measure cell expression levels 
of nitrite and nitrate, which represent the final products of nitric 
oxide oxidation pathways [24]. For this reason, Griess reagent was 
used in this work to evaluate NO produced by different cell types.
Materials and Methods
Chondrocyte culture
Primary chondrocytes were extracted directly from 3-6 days 
old Sprague-Dawley rats and then cultured in a low glucose (1g/L-
D-Glucose) HEPES (25mM) buffered DMEM (Dulbecco’s Modified 
Eagle Media, Sigma Aldrich) with Ham’s F12 with 1:1 ratio and 
culture medium supplemented with L-glutamine (2.5 mM U/mL), 
Penicillin (100 U/mL), Streptomycin (0.1 mg/mL), Amphotericin 
B or a fungizone (250 µg/ml), (Sigma Aldrich-UK) and 10% FCS 
v/v (fetal calf serum- PromoCell - UK). Routine sub-cultures were 
carried out upon reaching 80% confluency in sterile environment 
using a laminar flow hood by washing cells three times with Hank’s 
Balanced Salt Solution (HBSS) each time for five minutes, and by 
adding 1ml of 0.25% Trypsin-EDTA (Sigma Aldrich, UK) to detach 
cells. Once cells became rounded, detachment was stopped by the 
addition of 2ml medium containing 10% FCS. Cells were centrifuged 
at 1500 rpm, and then diluted using complete medium and counted 
using a haemocytometer. Cells were plated with an initial cell density 
of 100,000 cell/ml, culture flaks were always incubated in a 5% CO2 
air jacket controlled incubator at 37 °C. Following the third passage 
chondrocytes were seeded onto 1cm2 sterile glass cover slips in 35mm 
petri dishes at a density of 50,000 cells/ml (15.6×103 Cells/cm) and 
left for two days to reach 100% confluency before applying the three 
different treatments, i.e. control, and WIN55, 212-2 (WIN-2; SIGMA- 
ALDRICH, UK) at final concentrations of 1 µM and 2 µM. Treated 
chondrocytes were then incubated at 37 ºC in humidified atmosphere 
with 5% CO2 for 16 hours before investigating the changes in proteins 
and MMP-2 expressions. In order to quantitatively investigate the 
effect of WIN55, 212-2 on the chondrocytes protein expression, 
the same treatments were applied to 100% confluent chondrocytes 
cultured in 96-well plates. Similarly, NO expression by wounded 
chondrocyte monolayers for the same treatments was investigated 
over a period of 16 hours, where its value was recorded every 2 
hours to determine the changes in expression with time. Confluent 
cell cultures were wounded using a sterilized 1mm surgical plastic 
pipettes to reduce the possibility of contamination, and the timing 
window for total wound closure of a 300 µm width wound in MG-63 
bone cell monolayer was found to be about 30 hours. The cells were 
imaged every 5 hours using a phase contrast light microscope and 
photographed with a digital camera. 
Immunofluorescence staining for collagen Type-I and 
Type-II, fibronectin, and S100 protein
Treated chondrocytes were fixed using 4% formaldehyde and 
monoclonal anti collagen type-II (mouse IgG1 isotype) (SIGMA- 
ALDRICH, UK) solution was used as primary antibody and added 
to 9 petri dishes, 3 for each treatment. Similarly, monoclonal anti 
collagen type-1 (mouse IgG1 isotype) (SIGMA- ALDRICH, UK), 
monoclonal anti fibronectin (mouse IgG1 isotype) (SIGMA- 
ALDRICH, UK) and monoclonal anti S-100 (β-subunit, mouse IgG1 
isotype) (SIGMA- ALDRICH, UK) antibody solutions were each 
added to nine petri dishes. To confirm the specificity of the primary 
antibodies used (staining, i.e. –ve control), three petri dishes were not 
treated with primary antibodies. Ab-Alexor fluor 488 nM (Invitrogen, 
UK) solution was used as secondary anti-body and added to all the 
petri dishes. Protein expression was examined using an Eclipse 80i 
Fluorescence microscope with an objective lens of x20.
Elisa based method for detection of collagen type-I and 
type-II, fibronectin and protein S-100
Anti-collagen type-II antibody solution was added to three 
different treatment groups each consisting of 12 wells; the 1st group 
was untreated (control), the 2nd was treated with 1 µM WIN-2 and 
the 3rd was treated with 2 µM WIN-2. Similarly, Anti-collagen type-I, 
anti-S100 and anti-fibronectin antibody solutions were each added to 
the three different treatments. Anti-mouse IgG peroxidise conjugate 
(8 µg/ml) was used as secondary anti-body and tetramethyl benzidine 
(TMB; SIGMA- ALDRICH, UK) substrate was then applied and 
absorbance readings were measured at 630nm wavelenght and 
subtracted from absorbance readings measured when the wells were 
empty (blank). This experiment was repeated three times, giving a 
total of 36 readings for each different treatment group. 
MMP-2 immunoassay staining
12 samples were prepared for each of the three treatments, i.e. 
control, 1 µM WIN-2 and 2 µM WIN-2. Following incubation with 
these treatments for 16 hours, conditioned media was aspirated and 
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centrifuged at 1500 rpm for 5 minutes. An Elisa Kit (Invitrogen, UK) 
was used and staining steps were in accordance with the manufactures 
supplied protocol. Optical density values were obtained using ELx 
800 (Bioteck instruments, USA) at wavelength of 450nm.
Nitric oxide quantitative staining
After preparation of the nine different 96-well plates, supernatants 
were withdrawn from culture flasks and centrifuged at 1700 rpm for 
5 minutes. In a 96-well plate, 100 µl of each well was mixed with 
100 µl Griess reagent (SIGMA- ALDRICH, UK) and incubated at 
room temperature for 10 minutes. After incubation absorbance was 
measured using an absorbance micro-plate reader (ELx 800, Bioteck 
instruments, USA) at a wavelength of 570 nm. This experiment was 
repeated 3 times.
Statistical analysis
Quantitative staining readings were tested for normality using 
a Kolmogorov Smirnov test. Normally distributed data (p>0.05) 
were analysed using SPSS via ANOVA test followed by post Hoc 
Bonferroni tests. Kruskal-Wallis test and serial Mann Whitney tests 
were used for non-normally distributed data (p<0.05). Statistical 
tests were performed such that a p value of < 0.05 was considered as 
indicating a significant difference.
Results
Immunofluorescence and ELISA based staining for 
collagen type-II and collagen type-I of chondrocytes 
treated with 1 µM and 2 µM of WIN55, 212-2
Immunofluorescence and ELISA based staining of the 
chondrogenic protein collagen type-II indicated that untreated cells 
and cells treated with 1 µM and 2 µM of WIN-2 expressed type-II 
collagen distributed around the cell membrane. However, there 
seemed to be an increase in the secretion of collagen type-II by 
primary chondrocytes treated with 1 µM of WIN-2 (0.341 ± 0.007SD) 
compared to control groups (0.275 ± 0.008SD) (P<0.05) (Figure 
1A-C and Figure 1G), with the increase in collagen being associated 
with the formation of an intercellular Type II collagen network 
(Figure 1B). In comparison, treating chondrocytes with 2 µM of 
WIN-2 seemed to reduce collagen type-II secretion (0.240 ± 0.005SD) 
(P<0.05) compared to control groups (Figure 1C and 1G).
Using immunofluorescence staining of primary chondrocytes 
monolayer, a very weak expression of collagen type-I was visualized 
mainly as part of the cell membrane for the 3 different treatments. As 
shown in Figures 1D-F and 1H, collagen type-I was mostly expressed 
by untreated chondrocytes with an optical density reading of 0.210 
± 0.010SD. This value is ~33.3 % higher than the 0.140 ± 0.005SD 
produced by cells treated with 1µM WIN-2 (P<0.05). Similarly, 
chondrocytes treated with the higher concentration of 2µM WIN-2 
expressed a lower optical density reading, but it was only ~ 16.2% 
lower than control conditions at a value of 0.176 ± 0.009SD (P<0.05) 
(Figure 1H). Type-I collagen was localized around the cell membrane 
as part of the extracellular matrix (ECM) for control groups only 
(Figure 1D).
Immunofluorescence and ELISA based staining for S100 of 
chondrocytes treated with 1 µM and 2 µM of WIN55, 212-2
Out of the 4 proteins stained, the differentiation protein S100 
seemed to be highly expressed with the highest immunofluorescence 
Figure 1: Immunofluorescence staining of collagen type II and type I (green). 
The green colour shows positive staining for collagen type II and type I in 
control conditions (A and D), 1 µM WIN-2 (B and E) and 2 µM WIN-2 (C and 
F). Individual cell nuclei are stained blue (Dapi stain). [Scale bar = 100 μm]. 
Arrows in Figure 1B show the increase in collagen being associated with 
the formation of an intercellular Type II collagen network. Optical density 
readings (±SD) at 630nm following immunoperoxidase staining of deposited 
collagen type II (G) and collagen type I (H) following 16 hours incubation 
with 1 µM WIN-2, 2 µM WIN-2 and control conditions (*= p<0.05) (n=36).
Figure 2: Immunofluorescence staining of S100 and fibronectin (green). 
The green colour shows positive staining for S100 and fbronectin in control 
conditions (A and D), 1 µM WIN-2 (B and E) and 2 µM WIN-2 (C and F). 
Individual cell nuclei are stained blue (Dapi stain). [Scale bar = 100μm]. 
Optical density readings (± SD) at 630nm following immunoperoxidase 
staining of deposited S100 (G) and fibronectin (H) following 16 hours 
incubation with 1 µM WIN-2, 2 µM WIN-2 and control conditions (*= p<0.05) 
(n=36).
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staining intensity as shown in Figure 2A-C. Not only surrounding 
the nucleus of chondrocytes, but also predominant around the cell 
membrane in the ECM. Chondrocytes treated with 1 µM of WIN-2 
seemed to produce the highest expression of S100 (0.655 ± 0.017SD) 
(Figures 2B and 2G) which is ~25% higher than control groups (0.510 
± 0.021SD). The higher concentration of WIN-2 showed an average 
optical density of only 0.491 ± 0.021SD (P<0.05) which is lower than 
both control and 1 µM of WIN-2.
Immunofluorescence and ELISA based staining for 
fibronectin of chondrocytes treated with 1 µM and 2 µM of 
WIN55, 212-2
Fibronectin was mainly observed as networks of bright 
fluorescence dots in the pericellular matrix as shown in Figure 
1D-F. The fluorescence intensity and optical density produced 
by chondrocytes treated with 2 µM of WIN-2 were the greatest, 
indicating the highest expression of fibronectin for this treatment 
compared to the other two treatments (Figures 1D-F and 1H). The 
lowest expressions were for untreated cells producing an optical 
density reading of 0.225 ± 0.011SD. In contrast, the highest reading 
was produced by chondrocytes treated with 2 µM WIN-2 (0.338 ± 
0.009SD), which was ~33.4% higher than untreated cells (P<0.05). In 
the same way, treating chondrocytes with 1 µM of WIN-2 increased 
the secretion of fibronectin by ~ 22.7% (P<0.05), where the optical 
density value was 0.291 ± 0.006SD.
Immunofluorescence staining of chondrocytes without 
primary antibodies
Figure 3 shows the images produced by phase contrast and 
fluorescence microscopy. The specificity of the primary antibodies 
was confirmed by the lack of specific staining because no primary 
antibodies were used.
Detection of MMP-2 secreted by chondrocytes treated 
with 1 µM and 2 µM of WIN55, 212-2 using an Elisa based 
method
As shown in Figure 4A, MMP-2 expression of chondrocyte 
monolayers was significantly lower than control groups after 16 
hours of incubation with WIN-2 (P<0.05). The Elisa based technique, 
therefore, revealed that MMP-2 secreted by chondrocytes treated 
with 1 µM and 2 µM of WIN55, 212-2 was ~23.6% and 51.6% lower 
than control groups, respectively.
Nitric oxide quantitative staining
As shown in Figure 4B, the three treatments showed similar NO 
expressions for the first two hours with very little difference (P>0.05). 
However, after two hours, a very large gap started to appear between 
the three treatments. Untreated chondrocytes expressed significantly 
(P<0.05) high levels of NO up to 8 hours, whereas WIN-2 at 2 µM 
induced the lowest NO expression (P<0.05) followed by the 1 µM 
WIN-2 with similar behaviour but slightly higher NO expression 
than 2 µM WIN-2. The remarkable differences in NO expression 
remained almost the same for the treated conditions over the 16 hour 
period whereas the control reached its peak at 8 hours and then the 
NO expression reduced up to 16 hours.
Discussion
In vivo, chondrocytes synthesize cartilage extracellular matrix 
including collagens, proteoglycans, and non-collagen proteins such as 
fibronectin (a glycoprotein) that bind to integrins on cell membrane. 
Moreover, type-II collagen is responsible for the ability of cartilage to 
resist tensile and shear stresses. Thus, collagen type-II is considered 
as a predominant protein in the formation of cartilage [25] and 
can be used as a chondrogenic marker [7]. On the other hand, it is 
a well-established fact that chondrocytes cultured in monolayers 
have propensity for losing their differentiated function [26]. This 
dedifferentiation to fibroblast like cells (fibrocytes) is marked by 
a reduction in the secretion of collagen type-II and increase in the 
Figure 3: Negative control staining: (a) Light microscope image and (b) 
Immunofluorescence DAPI staining of individual cell nuclei. [Scale bar 100 
μm].
Figure 4: A shows the optical density readings (± SD) at 450nm following 
immunoperoxidase staining of deposited MMP-2 following 16 hours 
incubation with 1 µM WIN-2, 2 µM WIN-2 and control conditions (n=12). B 
shows the optical density readings for NO (± SD) at 570nm following nitrate 
Greass reagent  staining  for chondrocytes treated with 1 µM WIN-2, 2 µM 
WIN-2 and control conditions over a period of 16 hours (n=36).
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secretion of type-I collagen [27]. For these reasons, the effect that 
the synthetic cannabinoid WIN-2 had on chondrocytes monolayer 
expression of both collagen type-II and type-I was investigated. All 
chondrocyte monolayers, including control groups, secreted collagen 
type-II, indicating a chondrocytic phenotype. However, there were 
variations in the levels of collagen type-II secreted by the chondrocytes 
following the 3 different treatments.
Results reported previously [2] showed that the synthetic non-
specific cannabinoid WIN-2 at 1µM significantly increased the rate 
of wound closure, proliferation and collagen type-II expression. 
Also interestingly, as seen in Figures 1D-F and 1H, collagen type-I 
secretion was reduced by the same treatment. Therefore, WIN-2 
increased chondrocytes differentiation which might have led to an 
increase in cell migration and proliferation. A similar study [28] is in 
good agreement with current findings, i.e. in monolayers, migratory 
chondrocytes express more collagen type-II and less collagen 
type-I compared to static chondrocytes. It is also reported [29] that 
chondrocytes are expected to be more mobile than fibrocytes, and in 
monolayers, active motile chondrocytes may be more differentiated 
expressing higher concentrations of type-II collagen compared to less 
active ones. 
Other factors affecting the differentiation status of chondrocytes 
include interleukin-1beta (IL-1β) a major catabolic pro-inflammatory 
cytokine involved in cartilage destruction which is known to induce 
chondrocyte dedifferentiation [9]. WIN-2 has been found to strongly 
inhibit IL-1β signaling pathway in human astrocytes in a cannabinoid 
receptor-independent manner [30]. In the present study there is also a 
possibility that WIN-2 may have induced chondrocyte differentiation 
by inhibiting IL-1β because blocking CB2 receptor with AM-630 
(CB2 antagonist) did not significantly alter WIN-2’s effect on 
proliferation and wound repair rate of the chondrocyte monolayers 
reported previously [2]. Furthermore, both CB1 and CB2 receptors 
are coupled to heterotrimeric Gi/o proteins and activate the mitogen-
activated protein kinases (MAPK) extracellular signal regulated 
kinase ERK-1/2 [31], and stimulation of CB2 receptors activates 
ERK-1/2 pathway. ERK-1/2 pathway is required for regulating 
dedifferentiation and inflammation, where its inhibition was found 
to reverse chondrocyte induced dedifferentiation increasing collagen 
type-II expression [27].
Previous experiments indicated that chondrocyte monolayers 
treated with WIN-2 showed the roundest morphology compared 
to all the other treatments [2]. This can be supported by the critical 
role that ECM proteins like collagen type-II which play to modulate 
cellular phenotypes during chondrogenic differentiation [7]. 
Likewise, regardless of the treatment, chondrocytes expressed 
S100 protein confirming their chondrocytic phenotype (Figures 
2A-C and 2G). However, chondrocytes treated with the lower 
concentration of WIN-2 displayed the highest concentration of 
S100, whereas treating chondrocytes with the higher concentration 
of WIN-2 did not alter S100’s expression significantly (Figures 2A-C 
and 2G). Interestingly, it can be concluded from this work there is 
a direct correlation and an inverse correlation between S100 and 
collagen type-II and collagen type-I expressions, respectively. The 
treatment that induced the highest concentration of collagen type-
II produced the highest concentration of S100 and vice versa. S100 
is considered as a chondrocytes differentiation marker and in this 
regard, the expression of S100 has been reported [32] at different time 
intervals in a manually defected full thickness rabbit femoral condylar 
over a period of 120 days. S100 protein was present at higher levels 
in the early stages of the repair process. The presence of S100 protein 
identified cells with chondrogenic phenotype, and the lack of S100 
protein in other cells embedded in conventionally stained matrix 
suggested that these cells were no longer of a chondroid phenotype, 
especially that there was very low concentration of S100 in the 
hypertrophic layer from a fibrocellular surface layer [32]. The fact that 
this experiment was carried out in vivo and gave results that agreed 
with current findings increases the possibilities of chondrocytes 
responding similarly to WIN-2 in vivo. Moreover, chondrocytes from 
normal cartilage specifically from perivascular areas of the neonatal 
articular cartilage and in the deep zone of the infant articular cartilage 
demonstrated a much stronger positive S100 staining compared to 
cells found in the intermediate zone [11]. The protein synthesized in 
the deep zone was greater than other regions where the chondrocytes 
are relatively large and have many intra-cytoplasmic filaments, Golgi 
bodies, abundant endoplasmic reticulum and glycogen granules. 
In mild Osteoarthritis (OA), S100 positive chondrocytes were only 
found in the intermediate zone, but also found in clusters and 
metaplastic cartilage arising from bone marrow in severe OA [11]. 
These findings also suggest that an increase in the expression of S100 
indicates a rise in the metabolic activity of the cartilage matrix such 
as collagen and proteoglycan. Nonetheless, there is some evidence 
that S100 protein expression is upregulated in osteoarthritic cartilage, 
and may promote cartilage degeneration by activating the receptor 
for advanced glycation endproducts (RAGE) signalling pathway [32]. 
On the contrary, other studies have suggested that S100 may increase 
cellular proliferation [33] and that RAGE is not a universal receptor 
for S100 protein in other cell types which may apply to chondrocytes. 
In fact, S100 protein may have also contributed to the increase in 
the rate of wound closure associated with 1µM of WIN-2 treatment 
[2]. Then again, many studies have highlighted S100 protein’s 
proinflammatory activities, and its presence at elevated levels in 
serum and at extravascular sites in people affected with diverse 
inflammatory pathologies and infections [34]. S100 also promotes 
monocyte and neutrophils migration and may also be involved in 
leukocyte migration [34]. While in vitro, raised levels of S100 proteins 
may have increased chondrocyte migration in the same way it did 
with other cell types, it may also increase the leukocytes in synovial 
fluid of the joints. This accumulation of leukocytes may cause loss of 
articular cartilage proteoglycan.
It is well recognized that cellular interactions such as cell 
migration, adhesion and invasion between cells and the extracellular 
matrix are facilitated by integrins [35], and thus, it is not surprising 
that not only collagen type-II and S100, but also fibronectin may 
promote chondrocyte migration [35]. Likewise, previous studies have 
shown that chondrocyte differentiation and proliferation significantly 
elevated fibronectin secretion compared to control groups [28]. 
Accordingly, chondrocytes motility was increased by an average of 
3.3-fold by coating Boyden chambers with 1 μg/ml of fibronectin 
[28]. In other words, an increase in chondrocytes migration could 
be associated with an increase in the concentration of fibronectin. 
In this work and as reported previously [2], fibronectin expression 
was further increased (Figures 1D-F and 1H) whereas wound closure 
rate and cell proliferation were notably reduced by increasing 
the concentration of WIN-2 from 1 µM to 2 µM [2]. Essentially, 
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fibronectin is an ECM protein that is mainly responsible for cell’s 
attachment to the ECM by binding to integrins on cell membrane 
[35]. Consequently, an increase in adhesion would be expected 
with higher concentrations of fibronectin. Some studies have also 
suggested that some matrix components such as the fibronectin 
related protein fibulin and proteoglycans decorin and versican, may 
provide migratory inhibitory signals [36]. In agreement with this, 
other studies suggest cell migration is optimised by an intermediate 
degree of cell attachment and that very tight adhesion to the 
substratum reduces locomotive ability [37]. Therefore, the highest 
migratory rate would be expected with the optimum and not the 
highest fibronectin expression. At the transcriptional level, fibronectin 
is one of the macromolecules that regulate matrix metalloproteinase 
like MMP-2 [37]. For example, activation of MMP-2 and MMP-
9 was impressively down regulated for HT1080 fibrosarcoma cells 
cultured on fibronectin fragments compared to full length fibronectin 
[37]. Other cancer cells showing the same behaviour include breast 
cancer cells and colon cancer cells [38]. Cancer cells probably use the 
proteinase secreted by normal fibroblasts to facilitate tissue invasion. 
This does not mean that elevated levels of MMP-2 will increase normal 
cell migration, because cancer cells use this technique to induce self-
destruction of normal tissue removing any barriers, and making it 
easier to invade. Then again, maybe this is what happens in arthritic 
joints, leading to self-destruction of cartilage. Support for this view 
comes from evidence indicating elevated levels of fibronectin and 
fibronectin fragments in arthritic synovial fluid [39]. Fibronectin 
fragments were found to act as proteinases themselves or encourage 
fibroblasts to produce metalloproteinases [39], whereas normal intact 
fibronectin failed to induce MMPs expression in periodontal ligament 
[18], which is a connective tissue. Conversely, MMP-2 and other 
matrix proteinases were proven to promote fibronectin degradation 
[40]. This may explain the noticeable reduction in MMP-2 secretion 
caused by WIN-2 at a concentration of 1 µM which was further 
decreased by higher WIN-2 concentration of 2 µM (Figure 4A). In 
addition, WIN-2 reduced the secretion of MMP-9 in a murine model 
of cigarette-smoke induced lung inflammation; MMP-2 and MMP-9 
have similar substrates [41]. Therefore, numbers of studies suggest 
that cannabinoids may have antitumorigenic effects [42] because they 
reduce MMPs secretion and hence reducing healthy tissue invasion 
by sarcoma cells. Moreover, purified collagen type-II was cleaved 
by MMPs that are known to occur naturally [42], and MMP-2 has 
been described as a collagenase [43]. Yet, the lowest concentration of 
MMP-2 recorded did not correlate with the highest concentrations 
of the two collagens examined. Chondrocytes treated with 2 µM 
of WIN-2 secreted lower concentrations of collagen type-II, while 
reducing wound repair rates and cell proliferation, compared to 
control groups. This is probably due to reducing cell vitality, which 
will in turn reduce the protein expression. On the other hand, in 
vitro, osteosarcomic cells attachment to monomeric collagen type-
1 increased the amount of fully active MMP-2 independently to 
S100 expression by elevating TIMP-1 levels, while attachment to 3D 
fibrilar collagen type-I had an inverse effect [44]. Nevertheless, the 
fact that higher levels of collagen type-I was associated with lower 
levels of MMP-2 increases the relevance of current findings to 3D 
tissue models. 
Nitric oxide (NO) levels were nearly the same for the three 
treatments at zero hours (Figure 4B) which are released mainly by 
damaged chondrocytes [45]. WIN-2 at both concentrations used in 
this work managed to reduce NO expression up to 4 hours and then 
varied reduction took place until the end of the monitoring time in 
a dose dependent manner (Figure 4B). CB2 receptor agonists have 
been found [46] to stimulate anti-inflammatory healing reactions 
in activated microglia by inhibiting pro-inflammatory induced 
production of NO [46]. It has also been reported [47] that WIN-2 
(similar to this work) and cannabinol induced inhibition of NO 
(reduced in a dose related manner) by CB1 receptor antagonist, 
but not CB2 receptor antagonist [47]. The findings in this work are 
in agreement with others and suggest that WIN-2 may inhibit NO 
expression by activating the function of CB1 receptor.
Conclusion
Treatment of primary chondrocytes with 1 µM of WIN-2 increased 
the secretion of collagen type-II and decreased that of collagen type I. 
It can also be concluded that there is a direct and indirect correlation 
between S100 and collagen type II and type I expressions, respectively. 
The treatment that produced the highest concentration of collagen 
type II produced the highest concentration of S100 and vice versa and 
therefore S100 can be considered as the chondrocyte differentiation 
marker (also reported by others). The highest expression of fibronectin 
was associated with 2 µM of WIN-2 and the lowest expression was 
for the untreated cells. MMP-2 expression of treated chondrocytes 
with WIN-2 was found to be significantly lower than control groups. 
Untreated chondrocytes expressed significantly high levels of NO 
and that 2 µM of WIN-2 induced the lowest NO expression. Our 
findings, therefore, suggest that WIN-2 is able to improve cartilage 
wound healing by reducing the inflammation factors such as the 
matrix metalloproteinase-2 (MMP2) and nitric oxide (NO). This has 
the potential for reducing pain and improving the quality of life for 
patients. The overall concluding remark is that treating chondrocytes 
with WIN-2 may be used to improve cartilage repair by reducing 
the formation of fibrocartilage and increasing the synthesization of 
articular cartilage via inducing chondrocytes differentiation. This is 
particularly important due to the loss and abnormal remodelling of 
the cartilage extracellular matrix including collagens, proteoglycans 
and non-collagen proteins causing the critical pathogenic events of 
osteoarthritis [48].
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